Elegen

Elegen is an innovator in synthetic DNA manufacturing, offering a disruptive, cell-free production platform that eliminates the need for traditional cloning and bacterial fermentation. Its ENFINIA™ technology provides NGS-verified, high-complexity DNA up to 7 kb (and up to 15 kb in plasmids) with industry-leading error rates (1:70,000 bp) and rapid turnaround times of 6-8 business days. Recent price reductions to as low as $0.07/bp for linear DNA and the launch of its next-generation GEN II platform position the company to capture significant market share in the fast-growing gene synthesis market, particularly for applications in mRNA vaccine and therapeutic development.

ENFINIA™, a proprietary cell-free DNA synthesis platform combining microfluidics, AI, and robotics to produce long, clonal-quality, NGS-verified DNA without using living cells or traditional cloning.

Elegen competes in the gene synthesis market against major players like Twist Bioscience, GenScript, and Integrated DNA Technologies (IDT), which primarily use semiconductor-based oligo synthesis and in vivo cloning in E. coli. Elegen's key differentiators are its entirely cell-free process, which ensures speed and avoids sequence limitations of bacterial systems, and its delivery of NGS-verified, clonal-quality DNA without customer-side cloning. It positions itself as a premium service competing on total project time, not just cost-per-base.